Carbetocin and Oxytocin Compared for Postpartum Hemorrhage Prevention in Emergency C-Sections

Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide, often requiring urgent intervention. Current standard-of-care for PPH prevention following Caesarean section typically involves uterotonic agents like oxytocin, which stimulate uterine contractions to reduce blood loss. However, oxytocin has a relatively short half-life and can sometimes lead to side effects such as hypotension. Carbetocin, a synthetic long-acting oxytocin analog, offers a potential alternative with a more sustained effect, aiming to improve uterine tone and reduce the incidence of PPH, particularly in high-risk or emergency scenarios where rapid and prolonged uterine contraction is crucial.

This study was designed as a comparative trial to assess the effects of carbetocin versus oxytocin in preventing postpartum hemorrhage. The investigation focused on antenatal low-risk patients who initially planned for vaginal labor but required an emergency Caesarean section. The intervention involved administering either carbetocin intravenously or oxytocin (likely with ergometrine, as suggested by domain context) intravenously. The primary objective was to compare the effectiveness of these two uterotonic agents in reducing blood loss and preventing PPH in this specific patient population. The study aimed to evaluate the clinical outcomes and safety profiles associated with each treatment.

The provided abstract outlines the study's objective and design but does not present any specific findings, numerical data, or statistical outcomes. Therefore, no results regarding the comparative efficacy or safety of carbetocin versus oxytocin in preventing postpartum hemorrhage can be reported from this abstract. The abstract serves as a protocol or study description rather than a report of completed research findings.